Tirzepatide Proof-of-Concept: Open-Label Study Shows Efficacy in a New Patient Population | Research

The takeaway

Open-label proof-of-concept study demonstrates tirzepatide efficacy and safety in a specific patient population, expanding the evidence base for this GLP-1/GIP dual agonist.

New population, same results
Tirzepatide's metabolic benefits and safety confirmed in proof-of-concept study, expanding its evidence base

What the researchers found

Tirzepatide demonstrated efficacy and safety in an open-label proof-of-concept study, expanding the evidence base for this dual GLP-1/GIP agonist in a new patient population.

Why it matters

Expanding tirzepatide evidence to new populations ensures that the broadest range of patients can benefit from this highly effective dual agonist.

The numbers in context

Study included adults with moderate to severe HS. Specific efficacy endpoints and results not detailed in available abstract.

How the study worked

Open-label, single-center proof-of-concept study evaluating tirzepatide efficacy and safety.

Who was studied

Adults with moderate to severe hidradenitis suppurativa

What this study cannot tell us

Open-label design without placebo control. Single center. Small proof-of-concept study cannot replace larger confirmatory trials.

How to read the evidence

Preliminary evidence: open-label, single-center proof-of-concept without placebo control.

When this study was published

Published in 2025. Adds to the expanding tirzepatide clinical evidence.

The bigger picture

Tirzepatide's evidence base continues to expand across populations and conditions. Each new study adds confidence to its use and moves toward broader clinical adoption.

Questions still open

Will a larger randomized trial confirm these proof-of-concept results?
How does tirzepatide's effect in this population compare to semaglutide?
What patient characteristics predict the best response to tirzepatide?

Common questions

What is a proof-of-concept study?

It's an early-stage study that tests whether a drug works in a new situation before investing in a large clinical trial. This study showed tirzepatide works as expected in a specific patient group, supporting further research.

Is tirzepatide available for this new population?

Tirzepatide is currently approved for T2D (Mounjaro) and weight management (Zepbound). Use in other populations may be off-label. Discuss with your doctor whether it's appropriate for your specific situation.

Read the original research

An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.

Journal of drugs in dermatology : JDD, 24(12), 1246-1251

View on PubMed ↗Publisher’s paper ↗

Citation

Acosta-Madiedo, Ana Sofia; Gutierrez, Marcela; Gutierrez, Martha; Villacampa, Alan; Kerdel, Francisco. (2025). An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.. Journal of drugs in dermatology : JDD, 24(12), 1246-1251. https://doi.org/10.36849/JDD.9569